[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pediatric-hydrocephalus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pediatric-hydrocephalus":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100108054","hcrn-core-data-project-characterizing-patient-populations-in-the-hydrocephalus-clinical-research-network-hcrn-100108054",false,"NCT00670735","HCRN Core Data Project: Characterizing Patient Populations in the Hydrocephalus Clinical Research Network (HCRN)","Inclusion Criteria:\n\nInformation for all neurosurgical hydrocephalus patient events will be obtained from each HCRN Clinical Center and will be placed continuously into the Core Data Project. The first calendar year will be 2008, and data collection will continue for the duration of the existence of the HCRN. Neurosurgical hydrocephalus patient events include any operation for the treatment of documented hydrocephalus including the following:\n\n* Ventriculoperitoneal shunt\n* Ventriculoatrial shunt\n* Ventriculopleural shunt\n* Arachnoid cyst shunts\n* Subdural shunts\n* Lumboperitoneal shunts\n* Shunts replaced after treatment of infection\n* Shunts exposed during an operations but not revised\n* Endoscopic third ventriculostomies\n* Ommaya reservoir(s)\n* Ventricular access devices\u002Freservoirs\n* Subgaleal shunts.\n\nExclusion Criteria:\n\nThe following temporary cerebrospinal fluid (CSF) diversion procedures will not be included in the Core Date Project:\n\n• External ventricular drain(s)","ALL","18 Years",{"count":18,"type":19},1400,"ESTIMATED","OBSERVATIONAL","The Hydrocephalus Clinical Research Network (HCRN) has been established by philanthropic funding to conduct multi-institutional research (clinical trials and observational studies) on pediatric hydrocephalus. In addition to philanthropic funding, the HCRN has also received an NIH NINDS Challenge Grant to support the network infrastructure which allows for the conduct of this and other network studies. The HCRN consists of multiple Clinical Centers and the Data Coordinating Center (DCC). The HCRN Core Data Project will obtain data about all neurosurgical hydrocephalus events from the network Clinical Centers, and create a database to be used by HCRN investigators. The ongoing maintenance of the Core Data Project serves two main purposes: 1) it will help investigators understand the variability, progression, and current treatment practices for hydrocephalus in children, with an ultimate goal of better guiding and assessing therapeutic intervention and providing recommendations on patient care and, 2) it will provide pilot and descriptive data necessary for hypothesis generation and study design (i.e. preliminary power analyses, recruitment projections) for studies under development by the HCRN. This multi-institutional database will be maintained throughout the lifetime of the HCRN, and may be useful for tracking trends in pediatric hydrocephalus over time. The Core Data Project will be an invaluable resource to the HCRN and will help stimulate new research protocols, identify potential need for future expansion of the network to incorporate additional patient populations, and provide a descriptive understanding of children with hydrocephalus cared for within the network.",[23],"Pediatric Hydrocephalus",[23],"RECRUITING","2026-05-11",{"date":28,"type":29},"2026-05-14","ACTUAL",{"date":31,"type":4},"2008-04",{"date":33,"type":19},"2029-12",{"name":35,"class":36},"University of Utah","OTHER",14,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":4,"eligibilityCriteria":43,"healthyVolunteers":11,"sex":15,"minAge":44,"maxAge":16,"enrollmentInfo":45,"targetDuration":4,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":61,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100635064","phase-4-efficacy-and-cost-effectiveness-of-topical-vancomycin-powder-in-preventing-pediatric-ventriculoperitoneal-shunt-infections-across-different-etiologies-100635064","NCT07547826","Efficacy and Cost-Effectiveness of Topical Vancomycin Powder in Preventing Pediatric Ventriculoperitoneal Shunt Infections Across Different Etiologies","Inclusion Criteria:\n\nPatients will be enrolled in the study if they meet all the following criteria:\n\n* Age Range: Paediatric patients from birth (neonates) up to 18 years of age.\n* Indication: Patients undergoing primary (first-time) Ventriculoperitoneal (VP) shunt insertion.\n* Aetiology: Hydrocephalus due to congenital causes, post-haemorrhagic, or post-inflammatory origins.\n* Consent: Written informed consent provided by the parents or legal guardians.\n\nExclusion Criteria:\n\nTo ensure that the infection rate is strictly related to the surgical procedure and not to external chronic factors, patients with the following will be excluded:\n\n* Tumor-related Hydrocephalus: Due to the impact of malignancy, chemotherapy-induced immunosuppression, or potential radiotherapy on wound integrity.\n* Co-morbidities: Patients with Diabetes Mellitus, chronic renal failure, or known immunodeficiency disorders (to isolate paediatric physiological response).\n* Active Infection: Clinical or laboratory evidence of systemic sepsis or meningitis at the time of surgery.\n* Hypersensitivity: Known history of allergy to Vancomycin.\n* Revision Surgery: Patients undergoing shunt revision or replacement due to previous infection within the last 3 months.\n* Local Skin Issues: Active dermatitis or infection at any of the planned incision sites.\n* Complex Hydrocephalus: Patients requiring additional concurrent neurosurgical procedures (e.g., tumor biopsy, Chiari decompression, or cyst fenestration) to avoid prolonged operative time as a confounding risk factor for infection.\"","1 Day",{"count":46,"type":19},164,"INTERVENTIONAL",[49],"PHASE4","Objectives\n\n* Primary:\n* To measure the reduction in VP shunt infection rates using topical vancomycin powder.\n* Secondary:\n* To compare efficacy across different Etiological Strata (Congenital, Post-hemorrhagic, post-inflammatory).\n* To analyze the microbiological profile of failed cases.\n* To compare the \"Time-to-Infection\" and shunt survival rates between the study and control groups using Kaplan-Meier analysis.\n* To evaluate the cost-effectiveness of TVP compared to the standard management and historical AIC data",[52,53,54,55,23,56,57,58,59,60],"Hydrocephalus","Ventriculoperitoneal Shunt Infection","Surgical Site Infection (SSI)","Cerebrospinal Fluid Shunt Infection","Hydrocephalus in Children","Hydrocephalus in Infants","Postoperative Complications","Prosthesis-Related Infections","Bacterial Infections and Mycoses",[62,63,64,53,65,66,67,68,69,70,71,72,73,74,75,76,77],"Topical Vancomycin Powder","Vancomycin Crystalline Powder","Biofilm Prevention","Congenital Hydrocephalus","Post-Hemorrhagic Hydrocephalus","Post-Meningitic Hydrocephalus","Cost-Effectiveness","Resource-Limited Settings","Pediatric Neurosurgery","Antibiotic Stewardship","Surgical Site Infection","Antibiotic-Impregnated Catheters","Cerebrospinal Fluid Shunt","Surgical Wound Infection","VP Shunt Infection","AIC","NOT_YET_RECRUITING","2026-04-17",{"date":81,"type":29},"2026-04-23",{"date":83,"type":19},"2026-05",{"date":85,"type":19},"2027-12",{"name":87,"class":36},"Assiut University",1]